Business
INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor
INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"Munich-based Dr. Schoser is a World-renowned Expert on the Molecular Mechanisms of Muscle Loss and Weakness, and Myotonic DystrophyDENVER, CO / ACCESSWIRE / July 12, 2018 / INTIVA BioPharma Inc. (\"INTIVA\" or the \"Company\") (OTC PINK: NTVA) today announced that Germany-based, Dr. Benedikt Schoser has been retained as an advisor to the Company. Dr. Schoser is the senior consultant neurologist and co-chair of the Friedrich-Baur Institute, Germany's major national referral center for rare neuromuscular diseases. In 2016 he received an additional degree in palliative medicine. Since 2016, Dr. Schoser has served as co-chair of the Scientific Muscle and Neuromuscular panel of the European Academy of Neurology and in 2018 became a Fellow of the European Academy of Neurology. His clinical and research interests are in the field of multisystemic neuromuscular diseases and metabolic and myotonic myopathies.Dr. Schoser is an Associated Professor of Neurology at the Ludwig Maximilians University at their campuses in both Hamburg and Munich. Since 2010 he has also been the head of the Interdisciplinary Center for Neuromuscular Disorders at the University's Munich campus. Dr. Schoser has authored and co-authored more than 200 articles in peer reviewed journals, and contributed more than 20 chapters to books on neurology and muscle pathology, primarily focused in the field of diagnostic features and translational therapeutic trials in myotonic dystrophies, myasthenic syndromes, metabolic myopathies, and inflammatory myopathies. He serves as a member of the Editorial Board of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and Journal of Rheumatology and until February 2017 was the past chair of the Scientific Board of Neuromuscular Centers.Rob Goldfarb, INITVA's Chief Operating Officer stated, \"We are excited that Dr. Schoser is part of our scientific team. Dr. Schoser is one of the world's top researchers in both molecular mechanisms of muscle loss and myotonic dystrophy. Dr. Schoser's professional focus is on the investigation of molecular mechanisms of muscle loss and weakness in patients, and most importantly, in translating research on the basic mechanism into clinical reality.\" Mr. Goldfarb also stated, \"Since INTIVA has a pending patent application for the use of cannabinoids and terpenes for the treatment of dystr...